Integrating MetScore with classical–basal identity establishes a two-axis framework that better explains metastatic behavior, prognosis, treatment response, and microenvironmental composition than the conventional one-axis model and provides a clinically testable strategy for transcriptome-guided patient stratification...
Raymond E. Preston, Hong-Yun Huang, Margaret A. Hall et al.· bioRxiv· 0 citations
In NRG Oncology/RTOG 1010, HER2‐targeted escalation did not improve survival or patient‐reported outcomes in localized esophageal adenocarcinoma. The study illustrates that biologic plausibility and metastatic success do not guarantee benefit in the curative‐intent setting and emphasizes the need for rigorous, patient‐...
T. J. Brown, N. Hornstein, U. Grewal et al.· Cancer· 0 citations
Abstract RAF1 alterations are rare in metastatic colorectal cancer (mCRC), occurring in roughly 0.5% of cases, and lack established treatment guidance. We present a patient with RAF1 S257L–mutated, RAS wild-type mCRC and concurrent type 1 Gaucher disease, whose baseline cytopenias precluded standard chemotherapy and cl...
A. Rose, Alix Rosenberg, U. Grewal et al.· The Oncologist· 0 citations
Background Cholangiocarcinoma (CCA) is an aggressive biliary malignancy with increasing incidence and poor prognosis. Although traditionally considered a disease of older adults, early-onset CCA (EOCCA; age <50 years) may represent a clinically distinct subgroup. Data evaluating diagnostic and treatment trajectories in...
U. Grewal, A. Nottke, B. Loeffler et al.· ESMO gastrointestinal oncolo...· 0 citations
Metastatic cell state is established as an independent and clinically actionable dimension of PDAC biology that complements classical–basal subtype classification and will inform chemotherapy backbone choice in KRAS inhibitor trials, as well as treatment following progression on KRAS inhibitor monotherapy.
Raymond E. Preston, Hong-Yun Huang, Margaret A. Hall et al.· Cancer Research· 0 citations
EO-SBNETs represent a rising and clinically distinct subgroup characterized by similar presentation and treatment but relatively favorable long-term outcomes compared with AO-SBNETs, suggesting potential biological differences warranting further investigation.
Matthew T. Gao, Rishi R. Patel, Jason Semprini et al.· American Journal of Clinical...· 0 citations
Differences in mutations of key genes including a lower prevalence of APC mutations and increased SMAD4 mutations in younger individuals provides further supporting evidence that early-onset CRC may represent a distinct biological subtype of CRC.
L. Liu, A. Rose, A. Samaddar et al.· ESMO gastrointestinal oncolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.